Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2016 - 2026)

Corvus Pharmaceuticals' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 173.45% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 173.45% increase from a year earlier, with the FY2025 full-year figure at $855000.0, up 35.28% from the prior year.
• Other Non-Current Assets advanced to $1.7 million in Q1 2026 per CRVS's latest filing, from $855000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.7 million in Q1 2026 and bottomed at $89000.0 in Q3 2023.
• The 5-year median for Other Non-Current Assets is $236000.0 (2022), against an average of $415823.5.
• Across the five-year window, Other Non-Current Assets plunged 78.11% in 2022 and surged 610.11% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $129000.0 in 2022, then slumped by 31.01% to $89000.0 in 2023, then jumped by 610.11% to $632000.0 in 2024, then surged by 35.28% to $855000.0 in 2025, then surged by 101.17% to $1.7 million in 2026.
• Per Business Quant, the three latest CRVS Other Non-Current Assets figures stand at $1.7 million (Q1 2026), $855000.0 (Q4 2025), and $852000.0 (Q3 2025).